Vaccine-Induced Systemic and Mucosal T Cell Immunity to SARS-CoV-2 Viral Variants

Using adjuvanted spike protein–based vaccines that elicit potent T cell responses, scientists assessed whether systemic or lung-resident CD4 and CD8 T cells protected against SARS-CoV-2 variants in the presence or absence of virus-neutralizing antibodies.